*In the apixaban trial (AMPLIFY), major bleeding and composite of major bleeding and clinically relevant nonmajor bleeding was less with apixaban than with LMWH/warfarin; in the rivaroxaban trial (EINSTEIN), major bleeding with rivaroxaban was less than with warfarin in the PE trial, but the same between the two treatment arms in the DVT trial; in the dabigatran trial (RECOVER), major bleeding with dabigatran and LMWH/warfarin was similar.